| Entry |
|
|---|
| Name |
Cariprazine hydrochloride (JAN/USAN);
Vraylar (TN) |
|---|
| Product |
|
|---|
| Formula |
C21H32Cl2N4O. HCl
|
|---|
| Exact mass |
462.172
|
|---|
| Mol weight |
463.8719
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG01305): | D09876<US> |
|
|---|
| Efficacy |
Antipsychotic, Dopamine receptor partinal agonist, Serotonin receptor partial agonist/antagonist |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]; CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AX Other antipsychotics
N05AX15 Cariprazine
D09876 Cariprazine hydrochloride (JAN/USAN) <US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Cariprazine
D09876 Cariprazine hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG01305 Cariprazine
D09876 Cariprazine hydrochloride
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG01305 Cariprazine
D09876 Cariprazine hydrochloride
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01305 Cariprazine
D09876 Cariprazine hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D09876 Cariprazine hydrochloride (JAN/USAN) <US>
Serotonin
HTR1A
D09876 Cariprazine hydrochloride (JAN/USAN) <US>
HTR2A
D09876 Cariprazine hydrochloride (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09876
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09876
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09876
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG01305 Cariprazine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG01305 Cariprazine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01305 Cariprazine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 29
1 C1x C 20.7900 -19.3900
2 C1y C 20.7900 -17.9900
3 C1x C 22.0500 -17.2900
4 C1x C 23.2400 -17.9900
5 C1y C 23.2400 -19.3900
6 C1x C 22.0500 -20.0900
7 C1b C 24.5000 -20.0900
8 C1b C 25.6900 -19.3900
9 N1y N 26.8800 -20.0900
10 C1x C 28.0700 -19.3900
11 C1x C 29.2600 -20.0900
12 N1y N 29.2600 -21.4900
13 C1x C 28.0700 -22.1900
14 C1x C 26.8800 -21.4900
15 C8y C 30.5200 -22.2600
16 C8y C 31.7100 -21.5600
17 C8y C 32.9700 -22.2600
18 C8x C 32.9700 -23.6600
19 C8x C 31.7100 -24.3600
20 C8x C 30.5200 -23.6600
21 X Cl 34.1600 -21.4900
22 X Cl 31.7100 -20.0900
23 N1b N 19.6000 -17.2900
24 C5a C 18.4100 -17.9900
25 N1c N 17.2200 -17.2900
26 O5a O 18.4100 -19.3900
27 C1a C 16.0300 -17.9900
28 C1a C 17.2200 -15.8900
29 X Cl 29.9600 -17.0100
BOND 30
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 5 7 1 #Down
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 9 14 1
16 12 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 18 19 1
21 19 20 2
22 15 20 1
23 17 21 1
24 16 22 1
25 2 23 1 #Up
26 23 24 1
27 24 25 1
28 24 26 2
29 25 27 1
30 25 28 1
|
|---|
